Trials / Recruiting
RecruitingNCT07121335
SMC Radiation Oncology SABR Cohort for Oligometastasis
Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.
Conditions
- Stereotactic Body Radiation Therapy (SBRT)
- Oligometastasis
- Oligoprogression
- ctDNA
- Patient-Reported Outcomes (PRO)
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Stereotactic body radiotherapy (SBRT) | Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions). |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2027-12-31
- Completion
- 2030-03-31
- First posted
- 2025-08-13
- Last updated
- 2025-08-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07121335. Inclusion in this directory is not an endorsement.